200 related articles for article (PubMed ID: 25457016)
1. The evolving picture of lower urinary tract symptom management.
Tubaro A; De Nunzio C; Puccini F; Presicce F
Eur Urol; 2015 Feb; 67(2):271-2. PubMed ID: 25457016
[No Abstract] [Full Text] [Related]
2. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
3. Male lower urinary tract symptoms: a riddle waiting to be solved.
Apostolidis A
Eur Urol; 2013 Sep; 64(3):408-10. PubMed ID: 23731722
[No Abstract] [Full Text] [Related]
4. Reply from authors re: Apostolos Apostolidis. Male lower urinary tract symptoms: a riddle waiting to be solved. Eur Urol 2013;64:408-10: a rationale for combination antimuscarinic-α-blocker therapy for male lower urinary tract symptoms.
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):410-1. PubMed ID: 23816274
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
[TBL] [Abstract][Full Text] [Related]
6. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.
Henningsohn L; Kilany S; Svensson M; Jacobsen JL
Aging Male; 2017 Dec; 20(4):266-276. PubMed ID: 28787230
[TBL] [Abstract][Full Text] [Related]
7. Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
Drake MJ; MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Herschorn S; Huang M; Stoelzel M; Siddiqui E
Urology; 2017 Jun; 104():1-4. PubMed ID: 28322904
[No Abstract] [Full Text] [Related]
8. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
[TBL] [Abstract][Full Text] [Related]
9. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
[TBL] [Abstract][Full Text] [Related]
10. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.].
Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851
[TBL] [Abstract][Full Text] [Related]
12. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms.
Romancik M; Pandian S; Drake MJ
Drugs Today (Barc); 2014 Dec; 50(12):803-11. PubMed ID: 25588085
[TBL] [Abstract][Full Text] [Related]
13. α-Blockers and antimuscarinics for male lower urinary tract symptoms: the search goes on.
Gratzke C; Andersson KE
Eur Urol; 2013 Jan; 63(1):166-7; discussion 168. PubMed ID: 22959051
[No Abstract] [Full Text] [Related]
14. Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men.
Chan R; Munoz A; Wenker EP; Whipple M; Miles B; Boone TB
Urology; 2016 May; 91():150-3. PubMed ID: 26829718
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem.
Angulo JC
Curr Med Res Opin; 2015 Nov; 31(11):1963-5. PubMed ID: 26368336
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK
Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
[TBL] [Abstract][Full Text] [Related]
18. Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms.
Matsukawa Y; Gotoh M
Int J Urol; 2020 Jan; 27(1):85-86. PubMed ID: 31538373
[No Abstract] [Full Text] [Related]
19. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Dimitropoulos K; Gravas S
Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
